FRANKLIN LAKES, N.J., March 24, 2014 – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced the election of Dr. Claire Pomeroy to its Board of Directors.
Dr. Pomeroy, 58, is an expert in infectious diseases and a long-time advocate for public health and patients, especially those with HIV/AIDS. She is currently President of the Albert and Mary Lasker Foundation, a private foundation that seeks to foster the prevention and treatment of disease and disability by honoring excellence in basic and clinical science, and through public education and research advocacy.
“Dr. Pomeroy’s passion for public health, research and healthcare policy, along with her breadth and depth of experience, will undoubtedly bring a valuable perspective to the Company,” said Vincent A. Forlenza, BD Chairman, Chief Executive Officer and President. “It is an honor to welcome her to the BD Board of Directors as we advance and evolve our strategy and seek to improve healthcare globally.”
Dr. Pomeroy is a member of the Board of Directors of PRIDE Industries and the Sierra Health Foundation, and also serves as a member of the board of governors for the Foundation for Biomedical Research and the board of trustees for Morehouse School of Medicine. Dr. Pomeroy is also a member-at-large-representative for the AAAS medical sciences section and was inducted into the Institute of Medicine in 2011.
Dr. Pomeroy received her bachelor’s and medical degrees from the University of Michigan and earned an MBA from the University of Kentucky. Dr. Pomeroy previously served as chief of infectious diseases and Associate Dean for research and informatics at the University of Kentucky, and as Dean of the University of California, Davis School of Medicine and CEO of the UC Davis Health System.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.